Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Myelodysplastic Syndromes 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Cardiotoxicity 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 47Rituximab 31fludarabine 29Specimen Handling 13Magnetic Resonance Spectroscopy 13Doxorubicin 13pirtobrutinib 11Vincristine 11Prednisone 11fludarabine phosphate 10Immunotherapy, Adoptive 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7glofitamab 7zanubrutinib 6pembrolizumab 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Electrocardiography × 1 year × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡